G1 THERAPEUTICS (GTHX) Director Buys $4,932,500.00 in Stock

G1 THERAPEUTICS (NASDAQ:GTHX) Director Fredric N. Eshelman acquired 250,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at $20.75 on Friday. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/11/18/g1-therapeutics-gthx-director-buys-4932500-00-in-stock.html.

Several large investors have recently made changes to their positions in GTHX. American International Group Inc. acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $130,000. California State Teachers Retirement System acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $319,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $364,000. Alps Advisors Inc. acquired a new stake in shares of G1 THERAPEUTICS in the second quarter valued at approximately $444,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of G1 THERAPEUTICS in the third quarter valued at approximately $568,000. Institutional investors own 35.28% of the company’s stock.

Several research firms recently weighed in on GTHX. Cowen and Company reiterated a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, November 8th. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $29.75.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

What are top analysts saying about G1 THERAPEUTICS? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for G1 THERAPEUTICS and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit